Nuveen’s Galectin Therapeutics GALT Stock Holding History

Nuveen’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$296K	Buy	+63,710	New	+$165K	﹤0.01%	3508
2025 Q2	–	Sell	-27,623	Closed	-$33.7K	–	3311
2025 Q1	$33.7K	Hold	27,623	–	–	﹤0.01%	3272
2024 Q4	$35.6K	Hold	27,623	–	–	﹤0.01%	3320
2024 Q3	$76K	Hold	27,623	–	–	﹤0.01%	3320
2024 Q2	$62.4K	Buy	+27,623	New	+$83.9K	﹤0.01%	3321
2021 Q2	–	Sell	-177,035	Closed	-$384K	–	3436
2021 Q1	$384K	Sell	177,035 -7,816	-4%	-$17.5K	﹤0.01%	3133
2020 Q4	$414K	Buy	184,851 +2,965	+2%	+$7.78K	﹤0.01%	3081
2020 Q3	$486K	Sell	181,886 -57	-0%	-$160	﹤0.01%	2965
2020 Q2	$556K	Buy	181,943 +51,921	+40%	+$131K	﹤0.01%	2856
2020 Q1	$255K	Buy	130,022 +22,750	+21%	+$55.4K	﹤0.01%	2954
2019 Q4	$307K	Sell	107,272 -14,942	-12%	-$51.9K	﹤0.01%	3003
2019 Q3	$449K	Buy	122,214 +41,251	+51%	+$149K	﹤0.01%	2977
2019 Q2	$336K	Buy	+80,963	New	+$351K	﹤0.01%	3099

Other funds holding GALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Nuveen's GALT Position: Q2 2026 in Review

Nuveen opened a new position in Galectin Therapeutics (GALT) in Q2 2026: 63,710 shares worth $296K. The stake represents ﹤0.01% of the portfolio and ranks #3508 among its holdings. This is a return to the name: Nuveen previously reported a position in GALT as recently as Q1 2025.

Nuveen first reported a position in GALT in Q2 2019 and has held it in 13 quarters since. The position peaked at $556K in Q2 2020. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

Nuveen held 63,710 shares of Galectin Therapeutics worth $296K as of Q2 2026.
Galectin Therapeutics was a new Nuveen position in Q2 2026.
Galectin Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3508 holding.
Nuveen first reported a position in Galectin Therapeutics in Q2 2019 and has held it in 13 quarters since.
Nuveen's Galectin Therapeutics position peaked at $556K in Q2 2020.
98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.